MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Success Prompts New Invetech Facility in San Diego

OUTSOURCING NEWS

Invetech's San Diego facility helps the firm cope with growth in the medical sector.
As a result of strong customer growth in North America, Invetech (Melbourne, Australia) has opened the doors to a new facility in San Diego.

The 15,000-sq-ft plant will be home to design, engineering, and contract manufacturing services. Invetech is a contract developer and manu-facturer of bio-medical devices, instruments, and custom automation. The company's business development team has been in North America for more than five years.

According to Invetech's vice president, Jari Palander, the new office will help the company provide the flexibility and responsiveness that contribute to commercial success for its clients. The new facility also helps the firm “bridge the gap between research, product development, and manufacturing.”

The cluster of biomedical companies nearby and the surrounding science-rich community can take advantage of Invetech's services as well. High-technology firms in the region are involved in manufacturing medical devices, point-of-care and molecular diagnostics, and living-cell processing.

Invetech plans to add more skilled employees in anticipation of market growth.

“Invetech is continually expanding its client base, and with increased activity in this region, we have aggressive growth plans for our new office,” says Richard Grant, the newly named vice president of operations for the San Diego location.

Grant will supervise the company's U.S. operations and its move to new sites. He will also oversee the growth of the California group, which includes additional experienced staff from the Melbourne headquarters.

“The facility will have the infra-structure necessary to provide an expanded local service to our clients, including specialized development labs, workshops, and contract manufacturing production area[s],” according to Grant.

Copyright ©2008 Medical Device & Diagnostic Industry

Continued Innovation

COVER STORY

Across all three of its business units, Advanced Medical Optics Inc. (AMO; Santa Ana, CA) continues to roll out a range of new technologies designed to position the company for future growth. Noteworthy product developments and launches over the past year include the following.

Cataract and Implant Technologies. In late 2007, AMO launched three new refractive technologies to the European market. The Tecnis one-piece intraocular lens (IOL) and the Tecnis multifocal acrylic IOL were introduced for the first time in any market. Meanwhile, the WhiteStar Signature phacoemulsification system, launched in the United States in April 2007, made its debut on the European market.

The IntraLase femtosecond laser
Laser Vision Correction. In April 2007, AMO completed its $808 million acquisition of IntraLase Corp. (Irvine, CA). “The addition of IntraLase's state-of-the-art femtosecond laser technology to AMO's unmatched portfolio of corneal and cataract products allows us to forge a new path for vision care with a full suite of technologies to address a lifetime of refractive needs,” says Mazzo.

For 2007, AMO's U.S. femtosecond procedure volumes grew 41.5% on a pro forma basis. Internationally, pro forma femtosecond procedure sales grew 84.2% during the year.

Eye Care. Following a widespread contact lens solution recall in the spring of 2007, AMO's eye care business relaunched its Complete Easy Rub multipurpose solution last August. The relaunch helped partly offset multipurpose solution sales declines. For 2007, multipurpose sales declined 59.8% to $59.2 million, which included about $41.5 million in returns and an estimated $84 million in lost sales related to the recall.

In addition, AMO's eye care business recently launched a new over-the-counter dry-eye drop, which represents a completely new category for the company—one in which AMO was not allowed to compete for three years following its spin-out from Allergan. Mazzo estimates that the market for such products stands at $500 million or more.

Copyright ©2008 MX

Roundtable Participants

ADVERTISING, DISTRIBUTION, & SALES

Mark Adams was appointed vice president of sales and marketing for CryoCor Inc. (San Diego) in November 2007. Adams has served at the management and executive levels with several electrophysiology companies, including EP Technologies, prior to its acquisition by Boston Scientific; Irvine Biomedical, prior to its acquisition by St. Jude Medical; EP Medsystems; and Instromedics. He can be reached via e-mail at madams@cryocor.com.




Dale Hagemeyer is a research vice president for the manufacturing sector of industry advisory services at Gartner Inc. (Stamford, CT). His area of expertise is in customer-facing processes and applications for the consumer goods and life sciences industries, including the biotech, pharma, and medical device sectors. He can be reached via e-mail at dale.hagemeyer@gartner.com.





Mark M. Miller has served as vice president of sales and marketing for Zonare Medical Systems Inc. (Mountain View, CA) since March 2003. Prior to joining the company, Miller served as vice president of ultrasound sales at Siemens Medical Solutions (Malvern, PA) from March 2001 to March 2003. He can be reached via e-mail at mmiller@zonare.com.



Marshall C. Solem is managing principal of ZS Associates' headquarters office in Evanston, IL, and until 2008 was the leader of the firm's medical products and services practice. His primary focus is working with medical device and diagnostics companies on issues of sales and marketing effectiveness, including go-to-market strategy, sales force effectiveness, and incentive compensation. He can be reached via e-mail at marshall.solem@zsassociates.com.


Copyright ©2008 MX